> Detailanzeige

Walsh, Tom; Casadei, Silvia; Lee, Ming K.; Pennil, Christopher C.; Nord, Alex S.; Thornton, Anne M.; Roeb, Wendy; Agnew, Kathy J.; Stray, Sunday M.; Wickramanayake, Anneka; Norquist, Barbara; Pennington, Kathryn P.; Garcia, Rochelle L.; King, Mary-Claire; Swisher, Elizabeth M.

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
  • Beteiligte: Walsh, Tom; Casadei, Silvia; Lee, Ming K.; Pennil, Christopher C.; Nord, Alex S.; Thornton, Anne M.; Roeb, Wendy; Agnew, Kathy J.; Stray, Sunday M.; Wickramanayake, Anneka; Norquist, Barbara; Pennington, Kathryn P.; Garcia, Rochelle L.; King, Mary-Claire; Swisher, Elizabeth M.
  • Erschienen: Proceedings of the National Academy of Sciences, 2011
  • Erschienen in: Proceedings of the National Academy of Sciences
  • Sprache: Englisch
  • DOI: 10.1073/pnas.1115052108
  • ISSN: 0027-8424; 1091-6490
  • Schlagwörter: Multidisciplinary
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> Inherited loss-of-function mutations in <jats:italic>BRCA1</jats:italic> and <jats:italic>BRCA2</jats:italic> and other tumor suppressor genes predispose to ovarian carcinomas, but the overall burden of disease due to inherited mutations is not known. Using targeted capture and massively parallel genomic sequencing, we screened for germ-line mutations in 21 tumor suppressor genes in genomic DNA from women with primary ovarian, peritoneal, or fallopian tube carcinoma. Subjects were consecutively enrolled at diagnosis and not selected for age or family history. All classes of mutations, including point mutations and large genomic deletions and insertions, were detected. Of 360 subjects, 24% carried germ-line loss-of-function mutations: 18% in <jats:italic>BRCA1</jats:italic> or <jats:italic>BRCA2</jats:italic> and 6% in <jats:italic>BARD1</jats:italic> , <jats:italic>BRIP1</jats:italic> , <jats:italic>CHEK2</jats:italic> , <jats:italic>MRE11A</jats:italic> , <jats:italic>MSH6</jats:italic> , <jats:italic>NBN</jats:italic> , <jats:italic>PALB2</jats:italic> , <jats:italic>RAD50</jats:italic> , <jats:italic>RAD51C</jats:italic> , or <jats:italic>TP53</jats:italic> . Six of these genes were not previously implicated in inherited ovarian carcinoma. Primary carcinomas were generally characterized by genomic loss of normal alleles of the mutant genes. Of women with inherited mutations, &gt;30% had no family history of breast or ovarian carcinoma, and &gt;35% were 60 y or older at diagnosis. More patients with ovarian carcinoma carry cancer-predisposing mutations and in more genes than previously appreciated. Comprehensive genetic testing for inherited carcinoma is warranted for all women with ovarian, peritoneal, or fallopian tube carcinoma, regardless of age or family history. Clinical genetic testing is currently done gene by gene, with each test costing thousands of dollars. In contrast, massively parallel sequencing allows such testing for many genes simultaneously at low cost. </jats:p>
  • Zugangsstatus: Freier Zugang